Seller record · Telehealth service

yourEra

By Peptide Alliance, Editorial publisherRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The terms refer to the Pharmacies as a category and the landing page says only that medication ships from licensed US pharmacies. 1 more criterion also fails; see the table below.

At a glance

yourEraTelehealth service

6/8criteria passed

Price: Printed on its own pages before sign-up
Sells: compounded semaglutide, compounded tirzepatide, NAD+, and 1 more
FDA letters: None on file

Partner link. The site earns a commission on care started through it. Funding

Visit yourEra See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded semaglutide and tirzepatide on a six-month plan, alongside NAD+ and a microdosing protocol. Its compounding disclosure is unusually plain, and every purchase link on its own home page returns a not-found page.

Operating entity YourEra, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	yourEra's hello page
S2	Prescription gating	PASS	yourEra's sign-up site
S3	Pharmacy identification	FAIL	yourEra's terms
S4	Compounding disclosure	PASS	yourEra's hello page
S5	Analytical documentation	FAIL	yourEra's hello page
S6	Business address	PASS	yourEra's hello page
S7	Price disclosure	PASS	yourEra's hello page
S8	Enforcement status	PASS	FDA's website

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed United States clinician reviews the intake and decides whether treatment is appropriate, stated repeatedly on the landing page.Source: yourEra's hello page.

S2PASSThe order path opens an intake rather than a cart. Its first screen asks a weight-loss goal and presents no payment field.Source: yourEra's sign-up site.

S3FAILNo filling pharmacy is named. The terms refer to the Pharmacies as a category and the landing page says only that medication ships from licensed US pharmacies.Source: yourEra's terms.

S4PASSThe landing page states that its compounded formulations have not been reviewed or approved by the Food and Drug Administration for safety or effectiveness, and names the four brand drugs they are not.Source: yourEra's hello page.

S5FAILNo certificate, lot report or purity document is published or linked anywhere on the site.Source: yourEra's hello page.

S6PASSThe landing page footer prints a street address with a suite number in Covington, Louisiana, beside a support email address.Source: yourEra's hello page.

S7PASSBoth drugs carry a monthly figure before intake. Each is the six-month plan price, and the term is stated only in the cancellation answer.Source: yourEra's hello page.

S8PASSNo FDA warning letter names the brand or the operating entity YourEra, Inc., and no action has halted the business.Source: FDA's website.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, NAD+, clinician-guided microdosing protocols.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells NAD+

Partner link. The site earns a commission on care started through it. Funding.

Visit yourEra

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.